

Under the Dome – Rare Disease Advocacy

Rare Bootcamp | PGPA Overview

November 2024

Policy, Government, & Public Affairs The Team





Vice President Policy, Government and Public Affairs Novato HQ



Lisa Kahlman

Executive Director Public Policy and Public Affairs Portland, OR (Field)



Julie Boyd

Senior Director State Government Affairs (West) Austin, TX (Field)



Erin Frey

Senior Director State Government Affairs (East) Raleigh-Durham, NC (Field)



Isabel Bueso

Public Affairs Specialist State Government Affairs (CA) Novato HQ



Policy, Government, & Public Affairs 2025 High-Level Priorities

Develop conducive global political environment to support ability of UGX to do business and support access & reimbursement of our key products Lead and support rare disease initiatives on the federal and state levels

Advance earlier diagnosis initiatives at the federal and state levels

3

Build global reputation as sought after thought partner and good neighbor with policy, patient, community and political leaders

3

- Patient Experience Lead efforts to put patients at the forefront from development through commercialization (e.g., have patient experience data included in drug applications and labels)
- Market Access Ensure that all rare diseases are treated as a priority for world-wide markets.
- Pricing & Reimbursement Ensure majority access to our products through proactive payer engagement, education, and advocacy on clinical unmet need and responsible pricing philosophy; ensure flexibility in payment models for innovative therapies, underpinning sustainability of healthcare systems and innovation
- Diagnostic Odyssey Lead efforts to shorten the timeline from diagnosis to access of approved therapies (e.g., newborn screening, genomic sequencing, diagnostic codes, etc.)
- Gene Therapy Engage with policy makers in innovative new thinking and approaches in overall clinical and manufacturing developments leading to approval and set the stage for launches by characterizing unmet need and burden of illness in peer-reviewed literature.
- Accelerated Development Streamline rare disease drug development by engaging with Health Authorities globally to shorten non-clinical / clinical / CMC development timelines thereby ensuring speedier assessment and approval including efforts around biomarkers, endpoint development, etc.
- Emerging Markets Raise awareness of ultra-rare diseases and encourage local definitions around "rare", "ultra-rare" and "orphan" as well as educate re advanced therapies (e.g., gene therapy, mRNA)

Political Environment in Which Government Affairs is Operating in 2024

U.S. Federal Government

Decision Making Bodies:

White House, Health and Human Services, FDA, Senate Finance Committee, Senate Health Education Labor and Pension Committee, House Energy and Commerce, Key State Legislators and District Reps, Rare Disease Caucus members

State Governments

Decision Making Bodies:

Governor's Office, Health Department Secretary, Medicaid Director, Senate and House Leadership, Senate and House Budget and Health Committee Chairs and Members, Key District Legislators, Rare Disease Councils, Biotech Caucus, Joint Budget Committees

Hot Topics:

New Administration Transition, Budget Constraints, Increase Health Coverage, Drug Pricing

Hot Topics:

Budget Constraints, High-Cost Drug Coverage

Ultragenyx Key Issues and Key States

Federal

- Healthcare Budgets and Access
- FDA Reforms
- Priority REview Voucher Reauth
- IRA Legislation/Drug Prices
- Rare Disease Caucus Issues
- Newborn Screening Reauthorization
- Ultrarare Incentives

State

- Budget line item, Medicaid reimbursements
- Pricing/transparency
- Newborn Screening
- Rare Disease Caucus
- Rare Disease Advisory Councils
- Value Based Arrangements Pay for Gene Therapy


Policy, Government, & Public Affairs Ultragenyx Elected Official Representatives

Governi	Novato	Brisbane	Miami	Utah	Woburn	Bedford	Sommerville	Texas
ng Entity	Office	Office	Office	Office	Office	Facility	Office	Office
U.S. Senate	SenElect Adam Schiff (D)	SenElect Adam Schiff (D)	Sen. Rick Scott (R)	SenElect John Curtis (R)	Sen. Ed Markey (D)	Sen. Ed Markey (D)	Sen. Ed Markey (D)	Sen. Ted Cruz (R)
	Sen. Alex	Sen. Alex	Sen. Marco	Sen. Mike Lee	Sen. Elizabeth	Sen. Elizabeth	Sen. Elizabeth	Sen. John
	Padilla (D)	Padilla (D)	Rubio (R)	(R)	Warren (D)	Warren (D)	Warren (D)	Cornyn (R)
U.S. House	Rep. Jared Huffman (D- 2)	Rep. Kevin Mullin (D-15)	Rep. Maria Elvira Salazar (R-27)	Rep. Celeste Maloy (R-2)	Rep. Katherine Clark (D-5)	Rep. Seth Moulton (D- 6)	Rep. Ayanna Pressley (D-7)	Rep. Michael McCaul (R-10)

Policy, Government, & Public Affairs Ultragenyx Elected State Representatives

Governing Entity	Novato Office	Brisbane Office	South San Francisco Office	Somerville Office	Woburn Office	Bedford Facility	Miami Office	Texas Office	Utah Office
Governor	Gov. Gavin Newsom (D)	Gov. Gavin Newsom (D)	Gov. Gavin Newsom (D)	Gov. Maura Healey (D)	Gov. Maura Healey (D)	Gov. Maura Healey (D)	Gov. Ron DeSantis (R)	Gov. Greg Abbott (R)	Gov. Spencer Cox (R)
State Senate	Sen. Mike McGuire (D-2)	Sen. Josh Becker (D-13)	Sen. Josh Becker (D-13)	Sen. Patricia Jehlen (D – 2 nd Middlesex)	Sen. Cindy Friedman (D-4 th Middlesex)	Sen. Michael Barrett (D-3 rd Middlesex)	Sen. Ileana Garcia (D – 36 th)	Sen. Charles Schwertner (R-5)	Sen. Derek Kitchen (D-2)
State Assembly	Assm. Damon Connolly (D-10)	Assm. Diane Pappan (D-22)	Assm. Diane Pappan (D-22)	Rep. Mike Connolly (D-26 th Middlesex)	Rep. Richard Haggerty (D-30 th Middlesex)	Rep. Ken Gordon (D- 21 st Middlesex)	Rep. Demi Busatta Cabrera (D – 114 th)	Rep. John Raney (R-14)	Rep. Dailey- Provost (D-24)
County Supervisor	Sup. Eric Lucan (Dist. 5)	Sup. David Canepa (Dist. 5) (San Mateo)	Sup. David Canepa (Dist. 5) (San Mateo)	(Middlesex) – no county government	(Middlesex) – no county government	(Middlesex) – no county government	Rebeca Sosa (Dist. 6)	Commissioner Nancy Berry (Precinct 3)	Arlyn Bradshaw (Dist. 1)
City Mayor	Mayor Mark Milberg (2024)	Mayor Coleen Mackin	Mayor Mark Nagales	Mayor Katjana Ballantyne (D)	Mayor Scott Galvin	Village Manager Matt Hanson	County Mayor Daniella Cava (D) City Mayor Francis Suarez (R)	Mayor Karl Mooney	Mayor Erin Mendenhall

Federal Coalition Engagements



Organization	Representative(s)		
Alliance for Regenerative Medicine Board Member	Karah Parschauer		
California Life Sciences Board Member	Erik Harris		
MassBio Board Member	Dennis Huang		
Rare Disease Company Coalition (Board member and Co-Chair of Federal Policy Committee)	Lisa Kahlman		


State Governing Landscape

Relevant Decision-Making Bodies

- Governors' offices
- Health Department Secretary/Commissioners
- Drug Utilization Review (DUR) Boards/Pharmacy & Therapeutics (P&T) Committees
- Medicaid Directors
- Senate and House leadership
- Senate and House Budget and Health Committee Chairs and members
- Key state legislators and district representatives
- Rare Disease Advisory Councils
- Rare Disease, Biotech and Life Science Caucus members


Policy, Government, & Public Affairs

Government Affairs Key States for 2025



ultrager


Rare Disease Advisory Councils by State



Ultragenyx Resources

- <u>PGPA Policy Page</u>
- <u>Newborn Screening Resources</u>
- Patient Advocacy Website





Opportunities to Engage – PAG Advocacy Organizations

- EveryLife Foundation Community Congress, Rare Disease Day, Rare Across America
- NORD State Councils, Proclamations
- Global Genes Community Conferences
- Institute for Gene Therapy Patient Advisory Council
- State Rare Disease Advisory Councils
- Zebra Network



Additional Resource



Find and Contact Elected Officials

ultrager

17 © 2023 Ultragenyx Pharmaceutical Inc. | Confidential and Proprietary